Airbus recorded orders and options for 123 planes, according to the aviation consulting firm IBA.iQ.Paris Air Showread more
Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
European aircraft manufacturer Airbus is betting travelers will want to fly long distances on smaller jets with the launch of its Airbus A321 XLR.Airlinesread more
The action reflects the evolving dynamic for U.S. companies that have done business with Huawei, which has been caught in the middle of growing U.S.-China trade tension.Technologyread more
The announcement comes after Trump blasted three countries because thousands of their citizens had sought asylum at the U.S. border with Mexico.Politicsread more
Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.
Shares of Biogen rose about 7 percent in premarket trading immediately following the announcement. (Get the latest
Tecfidera sales were about $993 million, helped by inventory stocking, topping consensus estimate of $930 million, compiled by Evercore ISI.
Total revenue rose 7.5 percent to $2.84 billion, beating analysts' average estimate of $2.71 billion, according to Thomson Reuters I/B/E/S.
Net income attributable to the company fell to $831.6 million in the fourth quarter ended Dec. 31, from $883.5 million a year earlier.
On a per share basis, earnings rose to $3.77 from $3.74 due to fewer shares outstanding.
Excluding special items, Biogen earned $4.50 per share, handily beating Wall Street expectations of $4.08.
Analysts had expected Biogen to report earnings of about $4.08 a share on $2.71 billion in revenue, according to a consensus estimate from Thomson Reuters.
Biogen, along with the rest of the biopharmaceutical sector, has been under pressure amidst the public's ongoing drug-pricing debate. Earlier this month on CNBC's "Closing Bell, " CEO George Scangos reflected on the impact of the hot button issue.
"I think it's interesting to look backwards because we have raised our prices of drugs, and we did use that money to bring forth new compounds," said Scangos at the time.
Last quarter, Biogen announced a restructuring that involved cutting 11 percent of its workforce.
—CNBC's Christine Wang contributed to this report.